ClinicalTrials.gg
RecruitingNCT05311254FOVOCIPUpdated Sep 14, 2023

A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia

A Phase 3 interventional study of Fosfomycin Calcium in Febrile Neutropenia, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Randomized phase 3 trial to compare efficacy and safety of oral fosfomycin versus ciprofloxacin to prevent febrile neutropenia in patients with acute leukemia or recipients of hematopoietic stem cell transplant.

Read the detailed description

Multicenter, prospective, randomized, open label phase III trial to assess the efficacy and safety of oral fosfomycin vs. oral ciprofloxacin in the prevention of febrile neutropenia in patients with acute leukemia who are treated with intensive chemotherapy and/or are recipients of a hematopoietic stem cell transplant.

Non-inferiority design.

156 patients will be recruited: 78 in each arm

02

Conditions studied

  • Febrile Neutropenia

Browse trials for

03

In context

Febrile Neutropenia

147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.

This study's planned enrollment of 156 is above the median of 120 across 95 interventional studies indexed under Febrile Neutropenia.

Browse Febrile Neutropenia studies →

Lead sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able to understand study procedures, comply with them, and provide written before any study-specific procedure.
  2. Adult subjects ≥ 18 years of age with acute leukemia diagnosis who are going to receive their first intensive chemotherapy cycle or adult subjects ≥ 18 years of age who are candidates to receive a first stem cell transplant.
  3. Expected neutropenia 100x109/L lasting at least seven days. In case of expected neutropenia range 100-500x109/L lasting seven days or more, at least one of the following risk factors for infection must be present:

    1. Performance status (, ECOG) ≥2.
    2. Expected mucositis grade 3-4.
    3. Age ≥65 years.
    4. Comorbidity Index (HCTI) ≥3.
    5. Serum albumin\< 35 g/L.
    6. Total dose of etoposide > 500 mg/m2
    7. Total dose of cytarabine > 1 g/m2
    8. Active or neoplasia at the moment of stem cell transplant.
  4. Performance status (Eastern Cooperative Oncology Group, ECOG) of 0 to 3.
  5. Adequate organ function defined as:

    Liver: , alkaline phosphatase, or \< 3 times the upper normal limit (unless it is attributable to tumor activity).

    Renal : creatinine ≤ 250 μmol/l (2.5 mg/dL) (unless it is attributable to AML activity).

  6. higher than 3 months.
  7. Women of must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective measures of birth control and must agree not to become pregnant or father a child while receiving any study therapy and for at least 3 months after completing treatment.

Exclusion criteria

Exclusion Criteria:

  1. to fluoroquinolones or fosfomycin.
  2. Treatment with broad spectrum antimicrobial therapy within 4 weeks of first study treatment.
  3. Prior Intensive chemotherapy or stem cell transplant. Treatment with hydroxyurea or used to control white blood cell counts are permitted.
  4. Fever of infectious origin or documented infection within 4 weeks of first study treatment.
  5. Presence of any severe psychiatric disease or physical condition that, according to the physicians criteria, contraindicates the inclusion of the patient into the clinical trial.
  6. Subjects that have participated previously in this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Fosfomycin

    Drug: Fosfomycin: oral capsules containing 700 mg of calcium fosfomycin, equivalent to 500 mg of active drug.

    Drug: Fosfomycin Calcium

  • Active comparator
    Ciprofloxacin

    Oral ciprofloxacin, tablets containing 500 mg of active drug.

    Drug: Fosfomycin Calcium

Interventions

  • DrugFosfomycin Calcium

    Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count \>0,5x109/L.

06

What researchers measure

Primary outcomes

  1. Febrile neutropenia of infectious origin

    Febrile neutropenia that requires antibacterial treatment.

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

Secondary outcomes

  1. Documented infections

    Rate and type of documented infections

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

  2. Use of broad spectrum antibiotics

    Index of days of antibiotics per hospitalization days. Antibiotics will be classified according the Watch/Reserve classification

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

  3. Overall survival

    Time frame: Time from the day of randomization to the date of death, whatever the cause of death, up to 12 weeks.

  4. Drug related adverse events

    Incidence of Adverse Events (AE), severity and type of AEs.

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

  5. Evolution of resistome

    Rate of patients colonized by multidrug resistant bacteria as determined by metagenomic sequencing

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

  6. Microbiome evolution

    Changes in the gut microbiome produced under both prophylactic strategies during the study period.

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

  7. Microbiological safety

    Rate of patients colonized by multidrug resistant bacteria as determined by surveillance cultures

    Time frame: Immediately after the intervention until febrile neutropenia develops, neutrophil count >0,5x109/L up to 60 days maximum

07

Study locations

1 of 1 sites recruiting
  • Instituto de Investigación Sanitaria del Principado de Asturias
    Oviedo, Asturias 33011, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Mar 2024, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Apr 5, 2022
StartActual
Mar 14, 2022
Primary completionEst.
Mar 14, 2024
CompletionEst.
Mar 14, 2024
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05311254
Lead sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Collaborators
Instituto de Investigación Marqués de Valdecilla, Instituto de Salud Carlos III
Responsible party
Teresa Bernal del Castillo (Principal investigator, Fundación para la Investigación Biosanitaria del Principado de Asturias) — Principal investigator
First posted
Apr 5, 2022
Start date
Mar 14, 2022
Primary completion
Mar 14, 2024 (estimated)
Completion
Mar 14, 2024 (estimated)
Last update
Sep 14, 2023

Study contacts

Teresa Bernal, MD PHD
Contact
bernalmaria@uniovi.es
+34 985108000 ext. 37613
Javier Fernandez Dominguez, BD
Contact
javifdom@gmail.com
+34985108000
Teresa Bernal, MD PHD
principal investigator · Hospital Universitario Central Asturias

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion